Enel X Romania to build 2.5 MW solar park for drug maker Antibiotice

The photovoltaic (PV) systems will be installed at Antibiotice's headquarters in Iasi, in the east of the country, and will cover a total surface area of 3.14 hectares, Enel X said in a press release.

The solar park will comprise 4,680 solar panels with an average annual output of 3,500 MWh. The project will help reduce Antibiotice's carbon footprint by more than 2,000 tonnes per year and cut its spending on electricity by 26.4%.

The project is part of a company plan to cover a third of its energy needs with power from renewable sources in the near future, Antibiotice general director Ioan Nani said.

Enel X Romania’s portfolio includes projects for companies in the food industry, retail, logistics centres and office buildings. By the end of 2021, it installed about 40,000 photovoltaic panels, contributing to the reduction of carbon dioxide emissions by approximately 3,700 tonnes per year, it said.

Antibiotice Iasi is a state-owned pharmaceutical company that develops and produces 157 generic drugs for human use, veterinary drugs and Nystatin, an active ingredient. The company employs over 1,300 at its research centre and production facilities based in Iasi.

The Romanian state through the health ministry holds a 53% stake in Antibiotice, retail investment fund SIF Oltenia owns 26.9% and the rest is in the hands of small shareholders.

The company's shares traded flat at 0.5440 lei as at 1136 CET on Tuesday on the Bucharest Stock Exchange.

(1 euro=4.9314 lei)